Hypera S.A (SA:HYPE3) — Market Cap & Net Worth
Market Cap & Net Worth: Hypera S.A (HYPE3)
Hypera S.A (SA:HYPE3) has a market capitalization of $2.83 Billion (R$14.42 Billion) as of June 17, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #5205 globally and #55 in its home market, demonstrating a -0.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hypera S.A's stock price R$20.50 by its total outstanding shares 703501969 (703.50 Million). Review Hypera S.A (HYPE3) total liabilities to assess the company's total debt and financial obligations.
Hypera S.A Market Cap History: 2015 to 2026
Hypera S.A's market capitalization history from 2015 to 2026. Data shows growth from $2.14 Billion to $2.83 Billion (5.23% CAGR).
Index Memberships
Hypera S.A is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BOVESPA Index
BVSP
|
$564.73 Billion | 0.50% | #36 of 80 |
|
Bovespa Brazil 50
IBX50
|
$476.32 Billion | 0.59% | #27 of 50 |
|
SAO PAULO SE IBX50 INDEX
IBXL
|
$457.81 Billion | 0.62% | #26 of 50 |
|
SAO PAULO SE IGCX INDEX
IGCX
|
$572.21 Billion | 0.49% | #38 of 155 |
|
IVBX IND
IVBX
|
$203.36 Billion | 1.39% | #21 of 45 |
Weight: Hypera S.A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hypera S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hypera S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Hypera S.A's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.72x
Hypera S.A's market cap is 2.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.62 Billion | $3.23 Billion | $1.18 Billion | 0.81x | 2.22x |
| 2017 | $3.86 Billion | $3.50 Billion | $964.94 Million | 1.10x | 4.00x |
| 2018 | $3.43 Billion | $3.72 Billion | $1.13 Billion | 0.92x | 3.04x |
| 2019 | $4.20 Billion | $3.29 Billion | $1.16 Billion | 1.28x | 3.61x |
| 2020 | $4.18 Billion | $4.09 Billion | $1.30 Billion | 1.02x | 3.23x |
| 2021 | $3.59 Billion | $5.94 Billion | $1.33 Billion | 0.60x | 2.70x |
| 2022 | $5.91 Billion | $7.55 Billion | $1.70 Billion | 0.78x | 3.48x |
| 2023 | $4.82 Billion | $7.91 Billion | $1.65 Billion | 0.61x | 2.93x |
| 2024 | $2.50 Billion | $7.44 Billion | $1.34 Billion | 0.34x | 1.86x |
| 2025 | $3.25 Billion | $7.70 Billion | $1.20 Billion | 0.42x | 2.72x |
Competitor Companies of HYPE3 by Market Capitalization
Companies near Hypera S.A in the global market cap rankings as of June 17, 2026.
Key companies related to Hypera S.A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Hypera S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Hypera S.A's market cap moved from $2.14 Billion to $ 2.83 Billion, with a yearly change of 5.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$2.83 Billion | -12.99% |
| 2025 | R$3.25 Billion | +30.24% |
| 2024 | R$2.50 Billion | -48.22% |
| 2023 | R$4.82 Billion | -18.40% |
| 2022 | R$5.91 Billion | +64.77% |
| 2021 | R$3.59 Billion | -14.19% |
| 2020 | R$4.18 Billion | -0.57% |
| 2019 | R$4.20 Billion | +22.42% |
| 2018 | R$3.43 Billion | -11.12% |
| 2017 | R$3.86 Billion | +47.61% |
| 2016 | R$2.62 Billion | +22.53% |
| 2015 | R$2.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Hypera S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.83 Billion USD |
| MoneyControl | $2.83 Billion USD |
| MarketWatch | $2.83 Billion USD |
| marketcap.company | $2.83 Billion USD |
| Reuters | $2.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more